Breaks Categories: News

WednesdayAug 02, 2017 11:18 am

NetworkNewsBreaks – Celsion Corporation (NASDAQ: CLSN) Trading Higher following Positive Translational Data from OVATION Study

Celsion (NASDAQ: CLSN) this morning reported “convincing evidence” of gene transfer and immune system activity from its OVATION Study combining the company’s GEN-1 gene-mediated immunotherapy with the standard of care for newly diagnosed patients with advanced ovarian cancer. “These translational research findings demonstrate that GEN-1 in ovarian cancer patients is biologically active and creates a shift in the tumor microenvironment in the peritoneal cavity in a dose-dependent manner and promotes a pro-immune T-cell population dynamic in the tumor microenvironment,” Dr. Khursheed Anwer, Celsion’s executive vice president and chief science officer, stated in the press release. “These distinct immunological changes in…

Continue Reading

WednesdayAug 02, 2017 10:22 am

NetworkNewsBreaks – Dow Clinches New Record, Surpassing 22,000 with Boost from Apple (NASDAQ: AAPL)

The Dow Jones Industrial Average this morning rocketed past the 22,000 mark, clipping a new milestone with a boost from Apple, Inc. (NASDAQ: AAPL). Shares of the tech giant are up 5.7% at a new 52-week high of $158.67 in morning trade. The Dow earlier this year crossed the 20,000 mark for the first time in its 120-year history and currently moves in a 52-week range of 17,883.56-22,036.10. For more on the Dow’s record performance, visit: http://nnw.fm/M1Skp More from NetworkNewsBreaks ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Close of $15 Million Investment from Cannabis Wheaton EyeGate Pharmaceuticals, Inc. (NASDAQ:…

Continue Reading

WednesdayAug 02, 2017 9:04 am

NetworkNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Close of $15 Million Investment from Cannabis Wheaton

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the completion of Cannabis Wheaton Income Corp.’s (TSX.V: CBW) previously detailed purchase of $15 million of ABcann common shares at an agreed upon valuation of $2.25 per share. “We are pleased to have completed the initial funding phase of our partnership with Cannabis Wheaton and to welcome them as new equity holders in ABcann,” Aaron Keay, chief executive officer of ABcann, stated in the news release. “The initial investment represents Cannabis Wheaton's first funding allocation and we look forward to future investment from them, as both companies advance our respective…

Continue Reading

TuesdayAug 01, 2017 12:08 pm

NetworkNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Enrolls First Patient in Phase 2b Trial of EGP-437 for Cataract Surgery

Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are down 8% in mid-day trade. The specialty pharmaceutical company this morning said it has enrolled the first patient in the phase 2b clinical trial to evaluate its EyeGate® II Delivery System and EGP-437 combination product for the treatment of pain and inflammation in patients that have undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens). Top-line data is anticipated by year-end 2017. Under an exclusive worldwide licensing agreement signed with Valeant Pharmaceuticals International, Inc. (NYSE: VRX) earlier this year, a subsidiary of Valeant has commercial and manufacturing rights to…

Continue Reading

TuesdayAug 01, 2017 12:06 pm

NetworkNewsBreaks – Skyline Medical, Inc. (NASDAQ: SKLN) Inks Binding LOI for Merger Transaction with CytoBioscience

Skyline Medical (NASDAQ: SKLN) shares are up 4% this morning on news that the company has signed a binding letter of intent for a merger transaction with CytoBioscience, a privately held biomedical company. CytoBioscience is a creator and manufacturer of devices used in human cell research and is focused on new therapeutic drug development. CytoBioscience also has relationships with hospitals and government entities that it aims to leverage to open new markets for Skyline Medical’s STREAMWAY® System operating room safety products. “This is a great opportunity for both companies. The CytoBioscience group has a deep pipeline of projects and contracts…

Continue Reading

TuesdayAug 01, 2017 9:02 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Dr. Chuanhai Cao to Medical Research Team

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Dr. Chuanhai Cao has joined its medical research team as a key advisor. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials,” Ram Mukunda, CEO of IGC, noted in the news release. “Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for…

Continue Reading

MondayJul 31, 2017 12:57 pm

NetworkNewsBreaks – China Internet Nationwide Financial Services, Inc. (NASDAQ: CIFS) Prices $20M Initial Public Offering

China Internet Nationwide Financial Services (NASDAQ: CIFS) this morning announced the pricing of its initial public offering of 2,023,146 of its ordinary shares at $10 per unit. The provider of financial advisory services to the underserved small-to-medium-sized enterprises (“SMEs”) market in China said its shares are expected to begin trading on the NASDAQ Global Market on August 8, 2017, under the symbol “CIFS.” FBR Capital Markets & Co. and B. Riley & Co., LLC are acting as joint book-running managers for the offering. The company has granted the underwriters a 45-day option to purchase up to 3,000,000 additional units at…

Continue Reading

MondayJul 31, 2017 12:16 pm

NetworkNewsBreaks – MagneGas Corp. (NASDAQ: MNGA) Reports Improvements in MagneGas2® Production; Shares at New 52-week Low

Shares of MagneGas (NASDAQ: MNGA) are down 4.8% mid-day, trading at a new 52-week low of $0.57. The company this morning reported a 150% improvement in MagneGas2® production rates and a 50% reduction in production costs since the introduction of Butanol as a feedstock in April 2017. “Operationally, the research, development and production of MagneGas2® is one of the largest contributors to our cost structure. The use of butanol positively impacts the Company's financial metrics in several ways. First, we are able to significantly reduce the labor hours required to produce our gas, which enables us to reallocate labor to…

Continue Reading

MondayJul 31, 2017 12:09 pm

NetworkNewsBreaks – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Updates on INSPIRE Study; Pulls from New 52-Week Low

Shares of InVivo Therapeutics (NASDAQ: NVIV) are down 27.5% mid-day, lifting off a new 52-week low of $1.70 set this morning. The company earlier today issued an update on the progress of its INSPIRE Study designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete thoracic spinal cord injury (SCI). InVivo reported overall patient improvements, as well as a temporary enrollment halt due to the death of a patient, unrelated to the company’s treatment. “The most recent patient to enroll into the INSPIRE study, who was implanted in late June 2017, passed away…

Continue Reading

MondayJul 31, 2017 12:04 pm

NetworkNewsBreaks – Mateon Therapeutics, Inc. (MATN) Shares Surge on Positive Initial Data from Phase 1b Study of OXi4503

Shares of Mateon Therapeutics (OTCQX: MATN) are up 26% this morning after the company released preliminary data from its phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The data show that two of four patients achieved a complete remission after one cycle of treatment. Additionally, there were no dose-limiting toxicities observed in the fifth cohort and OXi4503 continued to have a favorable safety profile. “Every dose of OXi4503 tested in this study has shown encouraging signs of efficacy and a favorable safety profile, with the highest…

Continue Reading